Aralez hasn't wasted time on its rebirth as a cardiovascular specialty pharma. A $175 million-plus agreement to buy AstraZeneca's Toprol XL franchise came hard on the heels of a deal for Merck & Co.'s clot-busting Zontivity--and the launch of its long-awaited aspirin combo pill Yosprala.
